Prescribing based on review in the multidisciplinary PCSK9i clinic
| Outcome | Patients, N=100 |
| Offered PCSK9i | 52 (52) |
| Initiated evolocumab Initiated alirocumab 150 mg Initiated alirocumab 75 mg Declined and started on a statin | 33 (33) 9 (9) 6 (6) 4 (4) |
| Not offered PCSK9i | 48 (48) |
| Continued on the same therapy Started ezetimibe Started statin therapy Discharged Declined Changed statin Modified diet | 13 (13) 10 (10) 12 (12) 7 (7) 2 (2) 3 (3) 1 (1) |
Data are n (%).
PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor.